Build status - In Progress

KCP-330-020

KCP-330-020
Recruiting
18 years - 99 years
All
Phase 2
6 participants needed
1 Location

Brief description of study

The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each 42 day cycle until disease progression, intolerability, consent withdrawal or unblinding in Phase 2, 3, and open-label portion of the study.

Detailed description of study

A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Liposarcoma
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 825937

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center